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P .007). This association was observed irrespective of the type of
GVHD prophylaxis given. There was no difference in chronic
GVHD (18/32 [56%] vs 43/77 [56%] in the mismatched and
matched cohorts, respectively; P  .99). Relapse rates were also
similar (49% vs 53%; P  .84). Actuarial 1-year OS was 56% for
the mismatched group and 54% for the matched cohort, with a
2-year OS of 40% and 35%, respectively (P .40). Among patients
mismatched at HLA-C, aGVHD incidence was 16/23 (70%), and
there was a signiﬁcant trend toward decreased 1 and 2-year survival
(45% and 22%, vs 60% and 44% in C-matched patients; P  .07).
There was no difference in relapse associated with HLA-C dispar-
ity. In Cox regression-adjusted for HLA-disparity, donor/recipient
age, gender disparity, stem cell source (BM vs PBSC), disease
status, and GVHD prophylaxis, there remained a trend toward
worse survival for patients mismatched at HLA-C (HR 2.1; P 
.09), and grade II-IV acute GVHD was the only statistically sig-
niﬁcant predictor of death (HR 4.7; P  .001). We conclude that
single antigen/allele mismatch in HLA-A, B, and DQ is permissi-
ble for URD NST, but HLA-C disparity should be treated with
caution.
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CONTRIBUTIONS OF KIR GENOTYPE AND HLA-C-ENCODED KIR LI-
GANDS TO THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Fischer, J.1; Ottinger, H.D.2; Ferencik, S.2; Schwan, M.A.1; Middleton,
P.G.3; Grosse-Wilde, H.2; Wernet, P.1; Dickinson, A.M.3; Uhrberg,
M.1 1. Institute for Transplantation Diagnostics and Cell Therapeutics,
Du¨sseldorf University, Du¨sseldorf, Germany; 2. Institute of Immunol-
ogy, University Hospital of Essen, Essen, Germany; 3. Department of
Haematology, School of Clinical and Laboratory Sciences, University of
Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
A hallmark of human natural killer cells is the expression of
killer-cell immunoglobulin-like receptors (KIR), which enable the
detection of changes in HLA class I expression. The KIR family is
highly polymorphic and characterized by interindividual dif-
ferences in the number of inherited genes, which vary from 7
to sometimes 14 different genes. The aim of this study was
to analyze the inﬂuence of KIR genes and HLA-encoded li-
gands on allogeneic SCT outcome. Statistical analyses of trans-
plantation outcomes in unrelated HLA-matched transplanta-
tion for chronic myeloid leukemia (CML; n  109) by
univariate and multivariate analyses exhibited a signiﬁcant inﬂu-
ence of HLA-C-encoded KIR epitopes on overall survival.
Whereas patients with 2 HLA-Casn80 allotypes (HLA-C group
1) had an overall survival (OS) at 6 years of 76%, patients with 1
or 2 HLA-Clys80 allotypes (HLA-C group 2) exhibited a sig-
niﬁcantly decreased OS of 54% (independent of transplant
source and disease status in logistic regression analysis). Among
the latter subgroup, those patients, who received a transplant from
a donor with 2 HLA-Clys80 allotypes had a substantially better
event-free survival (EFS  79%) than those who received a trans-
plant from a donor with 1 or 2 HLA-Casn80 allotypes (EFS 
40%). Next, generic typing for presence or absence of KIR genes
was employed to assess the contribution of KIR genotype on SCT
outcome. A subgroup of patients was deﬁned who received grafts
from donors with 1 additional stimulatory KIR gene compared to
the patient’s genotype (KIRS_D1). A beneﬁcial inﬂuence of the
KIRS_D1 constellation on OS was seen in the unrelated SCT
study described earlier, as well as in a related SCT study of
HLA-identical sibling donor transplantations (n  65). Moreover,
epistatic interaction was seen between KIR genes and HLA-C
epitopes; among the patients with 1 or 2 HLA-Clys80 allotypes,
the KIRS_D1 group performed signiﬁcantly better (OS  83%)
than the remaining patients (OS  47%). In summary, consider-
ation of donor/patient KIR genotypes in combination with patient-
encoded KIR ligands might lead to an improvement in donor
selection in SCT.
IMMUNE RECONSTITUTION
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THE GENERATION OF DONOR-DERIVED VIRUS-SPECIFIC CYTOTOXIC T
LYMPHOCYTES REACTIVE AGAINST CYTOMEGALOVIRUS AND ADENO-
VIRUS ANTIGENS FOR CLINICAL USE
Bollard, C.M.; Leen, A.; Huls, H.; Myers, G.D.; Sili, U.; Rooney, C.M.;
Helsop, H.E. Center for Cell and Gene Therapy, Baylor College of
Medicine, Houston, TX.
Cytomegalovirus (CMV) and adenovirus are major viral patho-
gens causing morbidity and mortality in immunocompromised
patients undergoing allogeneic stem cell transplantation. Previous
studies have shown that prophylactic adoptive immunotherapy
with donor-derived cytotoxic T lymphocytes (CTLs) directed
against Epstein-Barr virus (EBV) and CMV can effectively prevent
the clinical manifestations of these viruses. We have extended these
studies by generating CTLs from normal donor PBMCs that
should restore cellular immunity to both CMV and adenovirus
simultaneously. We have generated a clinical grade recombinant
adenovirus type 5 vector pseudotyped with a type 35 ﬁber
(Ad5f35pp65) carrying a transgene for the immunodominant CMV
antigen, pp65. We have developed a protocol using an initial round
of stimulation with autologous mononuclear cells transduced with
Ad5f35pp65, followed by 2 rounds of weekly stimulation with
autologous EBV-transformed lymphoblastoid cell lines (LCLs)
transduced with the same vector using MOIs of 10 and 100,
respectively. After 3 rounds of stimulation, 3 CTL cultures con-
tained a mean of 86% (range, 82%-95%) CD8ve and a mean of
9.5% (range, 5%-14%) CD4ve cells. Evaluable CTL lines
showed signiﬁcant cytotoxicity in chromium release assays against
autologous ﬁbroblasts and LCL infected with a CMV vector and
LCL infected with the Ad5GFP vector. The observed cytotoxicity
was speciﬁc because nontransduced LCLs, transduced and non-
transduced MHC-mismatched LCLs, and autologous PHA blasts
were not killed. ELISPOT assays on CTL demonstrated a mean of
459 (range, 284–634) and 497.5 (range, 402–593) numbers of cells
secreting interferon-gamma after stimulation with autologous
PBMC stimulated with CMV and adenovirus peptides, respec-
tively. Using MHC-peptide tetramers in a HLA-A2/B7ve donor
we have been able to demonstrate the simultaneous presence of
CD8ve cells recognizing peptide epitopes from CMV pp65
(range, 2.41%-9.08%) and adenovirus hexon (1.69%) in the CTL
culture. In summary, we have developed a protocol for the efﬁcient
generation ex vivo of CTL with virus speciﬁcity for CMV and
adenovirus. We are currently growing these CTL lines for clinical
use in a FDA-approved protocol to restore cellular immunity to
these viruses after allogeneic stem cell transplantation.
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ASPERGILLUS FUMIGATUS-SPECIFIC CYTOTOXIC T-CELL LINES GEN-
ERATED THROUGH USE OF ASP F16 PROTEIN-SPANNING POOLS OF
OVERLAPPING PENTADECAPEPTIDES
Ramadan, G.1; Davies, B.1; Kurup, V.P.2; Keever-Taylor, C.A.1 1.
Medical College of Wisconsin, Milwaukee, WI; 2. VA Medical Center,
Milwaukee, WI.
Invasive aspergillosis (IA) fungal infection is often lethal in im-
munosuppressed individuals, particularly patients undergoing
blood or marrow transplantation. Although ﬁrst-line defense
against IA is largely mediated by neutrophils and macrophages,
there is evidence that Th1 type T-cell response is essential in the
control of infection. We prepared 104 overlapping pentadecapep-
tides (11-aa overlap with previous peptide) spanning the coding
region of the aspergillus allergen, Asp f16, previously shown to
induce Th1-type cell responses in mice. These were used to prime
T-cell responses in healthy donors. PBMC from 5/5 donors pro-
liferated strongly to complete peptide pool (PPC)-pulsed autolo-
gous monocyte-derived dendritic cells (DC) generated by 2–3 days
of culture with GM-CSF and IL-4, pulsed, then matured for 2 days
with a cocktail of inﬂammatory cytokines. Cytotoxic T lymphocyte
(CTL) lines were generated from 2 donors by weekly priming of
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donor PBMC with PPC-pulsed DC. By week 3–4, both lines were
strongly cytotoxic and produced IFN- (but not IL-4) in response
to PPC-pulsed targets. CTL activity and IFN- production by
donor 1 was mediated by HLA-DRB1*0301-restricted CD4 T
cells. Screening with 21 smaller peptide pools, then with single
peptides from the positive pools identiﬁed the recognized pep-
tide as TWSIDGAVVRT. A database search of peptides likely to
be presented by DRB1*0301 narrowed the sequence to
WSIDGAVVR (aa 174–182) (WSI). Screening of PBMC from
DRB1*0301 donors by ELISPOT revealed IFN- response to
WSI in 5/6 donors. All donors responded to PPC. CTL activity
and IFN- production was mediated by HLA-B*3501-restricted
CD8 T cells for donor 2 and via small pool followed by single
peptide screening and a database search, 3 peptides were identiﬁed,
YFKYTAAAL (aa 2–10) (YFK), LPLCSAQTW (aa 14–22) (LPL),
and GTRFPQTPM (aa 192–200) (GTR). Two of the 3 peptides
were also presented by B*3503, YFK, and GTR, but 0/3 were
presented by B*3502 or B*3508. Supernatant from both CTL lines
was toxic to A. fumigatus conidia in a FUN-1 assay and CTL were
directly cytotoxic to A. fumigatus hyphae in an XTT assay. These
data demonstrate the ability of Asp f16 to induce Th1-type T cell
responses. Use of a pool of overlapping pentadecapeptides can
prime both CD4 and CD8 T cells and is not limited to
individuals of a given HLA type. This represents a unique ap-
proach to the prevention or treatment of IA in immunocompro-
mised patients.
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EX VIVO EXPANDED MYELOID PROGENITOR CELLS PROTECT NEU-
TROPENIC MICE FROM FUNGUS INFECTION
Domen, J.; Wahedi, M.; Danenberg, E.; Christensen, J.; Smith, S.;
Fong, T. Cellerant Therapeutics, Palo Alto, CA.
Our long-term goal is to develop a cell-based short-term bridg-
ing therapy to enhance resistance to pathogens and recovery from
infections after hematopoietic cell transplantation or chemother-
apy. The use of mature myeloid cells is limited by the large
numbers of cells needed, their very short half-life, and the inability
to cryostore these cells. Myeloid progenitor cells, on the other
hand, can be cryostored and can result in signiﬁcant protection
with fewer cells. Several populations, deﬁned by surface markers in
both humans and mouse, are part of the MP pool. These include
common myeloid progenitors (CMPs), granulocyte macrophage
progenitors (GMPs), and megakaryocyte erythroid progenitors
(MEPs). Preclinical models with murine MP, focusing on CMP
and GMP, have demonstrated that a single infusion, even with fully
allogeneic cells, can prevent fungus-induced mortality. To obtain
sufﬁcient cells for clinical use, we aim to derive MP from highly
puriﬁed HSC ex vivo, using the inevitable myeloid differentiation
that is observed during attempatients to expand HSC ex vivo to our
advantage. Highly puriﬁed mouse KTLS HSC, deﬁned as
CD117, CD90.1low, Linneg/low, and Sca-1, were sorted and
cultured under serum-free conditions to derive MP. Using a
4-growth factor cocktail (KitL, Flt3L, Tpo, and IL-6), we observed
an approximately 100-fold increase in MP relative to the number
of KTLS HSC plated over a 1-week culture period. A mouse
model was used to test the ability of these cells to protect mice
against fungus infection. Infection was induced by intravenous
injection of conidia derived from a clinical isolate of Aspergillus
fumigatus 8 days after fully myeloablative preconditioning and
HSC transplantation. These studies conﬁrm that MP derived from
HSC ex vivo retain the potential to protect severely neutropenic
mice from a normally lethal challenge with A. fumigatus. Moreover,
both syngeneic and fully allogeneic (AKR to C57BL/Ka,
C57BL/Ka to BALB/c) culture-derived MPs provide effective pro-
tection. Reconstitution analysis conﬁrms that protection does not
require long-term engraftment by the MP-derived cells in vivo.
These preclinical experiments indicate that large numbers of func-
tional MPs can be obtained from puriﬁed HSC by ex vivo expan-
sion.
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NK CELL KILLER IMMUNOGLOBULIN RECEPTOR (KIR) RECONSTITU-
TION AND INTERFERON PRODUCTION AFTER UNRELATED DONOR
(URD) TRANSPLANTATION IS ALTERED BY THE T-CELL CONTENT OF
THE GRAFT AND CORRELATES WITH ACUTE GVHD
Cooley, S.; McCullar, V.; Wangen, R.; Weisdorf, D.J.; Miller, J.S.
Blood and Marrow Transplant Program, University of Minnesota, Min-
neapolis, MN.
KIR ligand mismatched haploidentical T-cell depleted (TCD)
transplants prevent AML relapse, GVHD, and graft failure, but
similar outcomes are not achieved with the same strategy when
T-cell- replete (non-TCD) grafts are used. We hypothesized that
the variable clinical beneﬁt is due to differences in KIR reconsti-
tution and NK cell function affected by competing donor T cells,
which may dilute the beneﬁt of NK-cell alloreactivity. We studied
cryopreserved PBLs collected by the National Marrow Donor
Program Research Sample Repository from 93 URD transplant
recipients (48 TCD, 45 non-TCD) and their donors, who provide
perfect controls for the genetic determinants of the KIR repertoire.
At day 100, all recipients had an average 4-fold increased percent-
age in NK cells compared with their donors. Importantly, the
quality of these NK cells differed signiﬁcantly based on the T-cell
content of the graft. Recovered KIR expression (assessed by ﬂow
cytometry using a cocktail of 4 KIR antibodies, DX9, EB6, GL183,
and FES173) more closely resembled the donor NK cells in TCD
transplants (recipient:donor ratio of KIR NK cells 0.91 	 0.08,
n  37). In contrast, recipients of non-TCD grafts had a signiﬁ-
cantly diminished KIR ratio of 0.63 	 0.07 (n  35; P .017).
CD94 and NKG2A were increased in recipients in both groups,
and were reciprocally highest when KIR was lowest. We also tested
the function of the reconstituted NK cells by measuring their
IFN- production by intracellular cytokine staining after incuba-
tion with IL-12 and IL-18. Although donor IFN- was similar in
both groups, recipients of non-TCD grafts had increased IFN--
producing NK cells compared to TCD transplants (53.96	 4.47%
vs 34.86 	 5.7%, n  49; P  .006). Patients who developed acute
GVHD had a signiﬁcantly increased percentage of recipient NK
cells producing IFN- (51.81 	 3.76% vs 20.79 	 4.76%; P 
.0001) and a decreased KIR expression ratio (0.64	 0.06 vs 0.97	
0.13, n  49; P  .03), suggesting a direct relationship between
lower KIR expression and increased NK cell IFN- production.
These data show that T cells in the graft alter the KIR repertoire
and function of reconstituted, donor-derived NK cells after unre-
lated donor transplantation, which in turn affect clinical outcomes.
This supports the premise that exploiting the beneﬁt of NK-cell
alloreactivity may be best realized without T cells competing for
the same factors that control homeostatic expansion of NK cells.
46
ENGINEERING DONOR MESENCHYMAL CELLS WITH IL-7 HASTENS
NAIVE T CELL RECRUITMENT IN VITRO AND SUPPORTS IMMUNOLOGIC
RECONSTITUTION AFTER HSCT IN NOD/SCID MICE
Di Ianni, M.; Del Papa, B.; De Ioanni, M.; Terenzi, A.; Sportoletti, P.;
Moretti, L.; Falzetti, F.; Bonifacio, E.; Martelli, M.F.; Tabilio, A.
Hematology and Clinical Immunology Section, Department of Clinical
and Experimental Medicine, University of Perugia, Perugia, Italy.
Key players in human T-cell development after T- cell-depleted
allogeneic stem cell transplants are bone marrow stroma and in-
terleukin-7 (IL-7). We engineered human stromal cells with the
IL-7 gene and studied the effects on T cells in vitro and on in vivo
immunological reconstitution in NOD/SCID mice. Transduced
mesenchymal cells were negative for CD45 and CD14, positive for
CD90 (98.15%), CD105 (87.6%), and STRO-1 (86.7%) and stably
produced IL-7 (16.37	2SD pg/ml). In cocultures with T cells,
IL-7 engineered stromal cells inhibited PHA-induced T cell pro-
liferation (proliferation index, 3.6 vs 8.0 in untransduced cells and
65.8 in PHA alone), and in cocultures with immunoselected naive
T cells, they maintained the CD45RACD45RO- naive pheno-
type (resting naive cell count, 4.2 times more than controls). In
NOD-SCID mice, they homed to all organs (highest percentages
in liver and lung; overlapping signals in spleen, thymus, bone
marrow, heart, kidney, skin and gut; traces in brain). In a NOD/
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